Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial-Reference-Cited by-同舟云学术

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Published:2017-08-17 Issue:12 Volume:65 Page:2112-2118
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Pulido Federico¹,Ribera Esteban²,Lagarde María¹,Pérez-Valero Ignacio³,Palacios Rosario⁴,Iribarren José A⁵,Payeras Antoni⁶,Domingo Pere⁷,Sanz José⁸,Cervero Miguel⁹,Curran Adrián²,Rodríguez-Gómez Francisco J¹⁰,Téllez María J¹¹,Ryan Pablo¹²,Barrufet Pilar¹³,Knobel Hernando¹⁴,Rivero Antonio¹⁵,Alejos Belén¹⁶,Yllescas María¹⁷,Arribas José R³,Arribas JR,Montejano R,González-García J J,Montes M L,Bernardino J I,Pérez-Valero I,Castro J M,Mayoral M,Pulido F,Lagarde M,Bisbal O,Matarranz M,Hernando A,Domínguez-Domínguez L,Rubio R,Ribera E,Curran A,Navarro J,Burgos J,Ocaña I,Falco V,Santos J,Palacios R,Pérez I,González-Doménech C M,Ibarguren M,Goenaga M A,Rodriguez-Arrondo F,von Wichmann M A,Kortajarena X,Carmona M P,Llatzer H Son,Payeras A,Raya M,Salom A,Domingo P,Gutierrez M M,Mateo M G,Sambeat M A,Sanz J,de Miguel J,Casas E,Arranz A,Cervero M,Torres R,Infanta Elena H,Rodríguez-Gómez F J,Fajardó J M,Martínez-Marcos F J,Merino M D,Raffo M,Suárez-Lozano I,Clínico H,Tellez M J,Vergas J,Estrada V,Infanta Leonor H,Ryan P,Troya J,Cuevas G,Diez-Viñas V,Talaván T,Solís F J,de Mataró H,Barrufet P,Force L,del Mar H,Knobel H,González A,Lerma E,Villar J,Sofía H Reina,Rivero A,Camacho A,Machuca I,Brieva T,Rivero-Juárez A,Gatell J M,Rojas J,Podzamczer D,Van Den Eynde E,Acerete L,Navarro A,Diyacovo M S,de las Nieves H Virgen,Pasquau J,García C,Losa J E,Henriquez C A J,Portilla J,Giner L,Portilla I,Pampliega M,Boix V,Merino E,Reus S,Torrus D,Clotet B,Negredo E,Chamarro A,Corbasi P,Gil-Pérez D,Arazo P,Parras F,Ramírez M,Gutiérrez-Cuéllar I,Son Espases H,Riera M,Gil-Alonso L,Vilchez H,Yllescas M,Alejos B,Aznar E,Esteban H,González P,González S,de Miguel M,

Affiliation:

1. Hospital Universitario Doce de Octubre, imas12, UCM, Madrid

2. Hospital Universitari Vall d’Hebron, Barcelona

3. Hospital La Paz, IdiPAZ, Madrid

4. Hospital Clínico Universitario Virgen de la Victoria, IBIMA, Málaga

5. Hospital Universitario Donostia, Instituto de Investigación BioDonostia, San Sebastian

6. Hospital Son Llatzer, Palma de Mallorca

7. Hospital Santa Creu i Sant Pau, Barcelona

8. Hospital Príncipe de Asturias

9. Hospital Universitario Severo Ochoa, Madrid

10. Hospital Infanta Elena, Huelva

11. Hospital Clínico

12. Hospital Universitario Infanta Leonor, Madrid

13. Hospital de Mataró

14. Hospital del Mar, Barcelona

15. Hospital Universitario Reina Sofía, IMIBIC, Córdoba

16. Centro Nacional de Epidemiología

17. Fundación SEIMC-Gesida, Madrid, Spain

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/65/12/2112/21968140/cix734.pdf

Reference19 articles.

1. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis;Achhra;Lancet HIV,2016

2. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial;Cahn;Lancet Infect Dis,2014

3. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study);Perez-Molina;J Antimicrob Chemother,2017

4. Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M);Di Giambenedetto;J Antimicrob Chemother,2017

5. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial;Arribas;Lancet Infect Dis,2015

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes;AIDS;2023-12-11

2. Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy;AIDS Research and Human Retroviruses;2023-12-01

3. HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors;Biomedicine & Pharmacotherapy;2023-12

4. Two-drug antiretroviral regimens for HIV;BMJ;2023-09-01

5. Efficacy and safety of switching lamivudine-based dual therapies for the maintenance of virologic suppression in adults with HIV-1: a systematic review and network meta-analysis;2023-08-17